Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herceptin and Docetaxel in Androgen-Independent Prostate Cancer
NCT00005857Phase 2Completed
- Sponsor
- City of Hope
- Start
- Aug 2000
- Primary completion
- Oct 2002
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab in prostate cancer (PCa) (2 arms), sponsored by City of Hope. Primary endpoints: Efficacy and Toxicity. Started Aug 2000; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00005857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005857.